To access the full text documents, please follow this link: http://hdl.handle.net/10256/14145
dc.contributor.author | Blanco Silvente, Lídia |
---|---|
dc.contributor.author | Castells Cervelló, Xavier |
dc.contributor.author | Sáez Zafra, Marc |
dc.contributor.author | Barceló Rado, María Antonia |
dc.contributor.author | Garre Olmo, Josep |
dc.contributor.author | Vilalta Franch, Joan |
dc.contributor.author | Capellà Hereu, Dolors |
dc.date | 2017-06-02T10:02:20Z |
dc.date | 2017-06-02T10:02:20Z |
dc.date | 2017-02-13 |
dc.identifier.citation | 1461-1457 (versió paper) |
dc.identifier.citation | 1469-5111 (versió electrònica) |
dc.identifier.citation | 026726 |
dc.identifier.uri | http://hdl.handle.net/10256/14145 |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | Oxford University Press (OUP) |
dc.relation | http://dx.doi.org/10.1093/ijnp/pyx012 |
dc.relation | Reproducció digital del document publicat a: http://dx.doi.org/10.1093/ijnp/pyx012 |
dc.relation | International Journal of Neuropsychopharmacology, 2017, vol 20, núm. 7, p. 519-528 |
dc.relation | Articles publicats (D-CM) |
dc.rights | Attribution-NonCommercial 3.0 Spain |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by-nc/3.0/es/ |
dc.subject | Alzheimer, Malaltia d' |
dc.subject | Alzheimer's disease |
dc.subject | Assaigs clínics |
dc.subject | Clinical trials |
dc.title | Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16.106 Patients |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |